La cadena de opciones muestra datos clave de las opciones de acciones de aTyr Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para aTyr Pharma..

aTyr Pharma (NASDAQ:ATYR) Bolsa, Cadena de Opciones

ATYR PHARMA INC

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR

News

Legal

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of aTyr Pharma, Inc. Common Stock and Sets a Lead Plaintiff Deadline of December 8, 2025

aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman

Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company

aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline Alert: Shamis & Gentile, P.A. Alerts Investors of Important Lead Plaintiff Deadline of December 8, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

ATYR

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coya Therapeutics

Fortress Biotech

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

InflaRx

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immix Biopharma

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lite Strategy

Macrogenics

NewAmsterdam Pharma Company N.V. - Warrant

NewAmsterdam Pharma Co

OKYO Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Spruce Biosciences

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Comments

aTyr Pharma

aTyr Pharma (ATYR) Opciones

aTyr Pharma (NASDAQ:ATYR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL